Madison Technologies Inc (MDEX)

[RookieStockPicker]

MDEX Promotion today.

Tomorrow's Alert Is MDEX!



Good Evening Traders!!

If you missed yesterday's alert, hurry and add this stock to your radar!

At these levels MDEX looks super attractive to us and we see a lot of potentia upside right now!

With the marijuana industry so huge right now, we are always on the hunt for what could be the next big leader in the arena. MDEX is up to something that could quickly push them to the frontline! The best part is that its all still fairly recent which means the levels right now could be GROUND-FLOOR!

About the Company:

It was just this past summer that MDEX announced the signing of an Agreement closing the acquisition of a smokeless cannabinoid delivery technology commercially known as "CannaStrips."

CannaStrips is in advanced development of a number of additional smokeless delivery systems designed specifically for smokeless cannabinoid therapy.

The technology was developed over four years of formulation and testing. The results of those efforts encompass four smokeless cannabinoid delivery technologies -- oral strips, vapor oils, mist spray and droplets.

MDEX intends to license the CannaStrips technology, which will include proprietary equipment being leased to CannaStrip's licensees that have State approved marijuana production facilities and/or dispensaries.

The company plans to focus initially on: California, Colorado, and Washington State. Both Colorado and Washington State started allowing recreational marijuana legally this year. The market is enormous! Recent state estimates have revealed that Washington can expect $637 million in revenue by 2019, while Colorado can expect $174.5 million through the fiscal year that ends in 2017.


Cannabinoid Therapy:

There are a number of specific cannabinoids contained in marijuana and these cannabinoids have been found useful in the treatment and prophylaxis of a wide variety of oxidation associated diseases.

This includes: cataracts, sleep disorders, seizures and autoimmune diseases.

The cannabinoids are also believed to have particular application as neuroprotectants, for example in limiting neurological damage following ischemic invectives, such as stroke and trauma, or in the treatment of neurodegenerative diseases including: Alzheimer's disease, Parkinson's disease and HIV dementia.

The ability to separate the cannabinoids from the psychoactive THC can allow therapy free of the effects of THC.

As THC enters the brain, it causes the user to feel euphoric. In other words, high.

There are many people who want the benefits of marijuana WITHOUT the high!!

This is what makes MDEX so attractive to us.

The company has been able to separate specific cannabinoids and integrate them into their CannaStrips!

MDEX CEO Brent Inzer commented: "The ability to deliver cannabinoid therapy specific to a patients exact needs greatly increases the possibility for monitoring the effectiveness of the therapy and hopefully promoting clinical trails and further in depth cannabinoid studies and testing."

Brent Inzer:
Inzer's past success could quickly push MDEX to the top! In 2008 he was co-founder of Marijuana Medicine Evaluation Centers (M.M.E.C.) which in 2 years expanded into 14 standalone clinics.

M.M.E.C was the second largest provider of medicinal marijuana evaluations in the country with annual sales of over $6 million! In 2010 General Cannabis, Inc., a publicly traded company, acquired another Inzer Company, Synergistic Resources. Mr. Inzer continued on with General Cannabis as a consultant.

During his time with General Cannabis Inc the company grew from $500,000 in annual sales to over 20 million dollars in annual sales in 2012!!

Could he quickly get MDEX to multi-million dollars in annual sales? Hurry and start your research at: http://cannabinoidstrips.com

MDEX could be our next announcement to see gains of 100% or higher!


Good Luck!

-JPS